Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
NCT ID: NCT00115791
Last Updated: 2008-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
276 participants
INTERVENTIONAL
2004-06-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
RSD1235
IV
2
placebo
IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSD1235
IV
placebo
IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanz Pharma
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Astellas Pharma US, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigative Site
Birmingham, Alabama, United States
Investigative Site
Huntsville, Alabama, United States
Investigative Site
Gainesville, Florida, United States
Investigative Site
Orlando, Florida, United States
Investigative Site
Port Charlotte, Florida, United States
Investigative Site
Indianapolis, Indiana, United States
Investigative Site
Shreveport, Louisiana, United States
Investigative Site
Baltimore, Maryland, United States
Investigative Site
Lansing, Michigan, United States
Investigative Site
Petoskey, Michigan, United States
Investigative Site
Saint Paul, Minnesota, United States
Investigative Site
Tupelo, Mississippi, United States
Investigative Site
Holmdel, New Jersey, United States
Investigative Site
Cincinnati, Ohio, United States
Investigative Site
Amarillo, Texas, United States
Investigative Site
Houston, Texas, United States
Investigative Site
Richmond, Virginia, United States
Investigative Site
Tacoma, Washington, United States
Investigative Site
Marshfield, Wisconsin, United States
Investigative Site
Buenos Aires, , Argentina
Investigative Site
Buenos Aires, , Argentina
Investigative Site
Buenos Aires, , Argentina
Investigative Site
Buenos Aires, , Argentina
Investigative Site
Mendoza, , Argentina
Investigative Site
Calgary, Alberta, Canada
Investigative Site
Edmonton, Alberta, Canada
Investigative Site
Halifax, Nova Scotia, Canada
Investigative Site
Ottawa, Ontario, Canada
Investigative Site
Ottawa, Ontario, Canada
Investigative Site
Toronto, Ontario, Canada
Investigative Site
Montreal, Quebec, Canada
Investigative Site
Montreal, Quebec, Canada
Investigative Site
Montreal, Quebec, Canada
Investigative Site
Terrebonne, Quebec, Canada
Investigative Site
Santiago, Cironaria, Chile
Investigative Site
Aalborg, , Denmark
Investigative Site
Arhus C, , Denmark
Investigative Site
Esbjerg, , Denmark
Investigative Site
Fredericia, , Denmark
Investigative Site
Frederikssund, , Denmark
Investigative Site
Herlev, , Denmark
Investigative Site
Hjørring, , Denmark
Investigative Site
Holstebro, , Denmark
Investigative Site
Horsens, , Denmark
Investigative Site
Hvidovre, , Denmark
Investigative Site
København NV, , Denmark
Investigative Site
København S, , Denmark
Investigative Site
Køge, , Denmark
Investigative Site
Magdalena de las Salinas, , Mexico
Investigative Site
Malmo, , Sweden
Investigative Site
Mölndal, , Sweden
Investigative Site
Örebro, , Sweden
Investigative Site
Stockholm, , Sweden
Investigative Site
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cardiome 1235-0504
Identifier Type: -
Identifier Source: secondary_id
04-7-010
Identifier Type: -
Identifier Source: org_study_id